Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice:Results from the CVD-REAL study by Kosiborod, Mikhail et al.
Syddansk Universitet
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-
inhibitors versus other glucose-lowering agents in real-world clinical practice
Results from the CVD-REAL study
Kosiborod, Mikhail; Birkeland, Kåre I.; Cavender, Matthew A.; Fu, Alex Z.; Wilding, John P.;
Khunti, Kamlesh; Holl, Reinhard W.; Norhammar, Anna; Jørgensen, Marit Eika; Wittbrodt,
Eric T.; Thuresson, Marcus; Bodegård, Johan; Hammar, Niklas; Fenici, Peter; the CVD-REAL
Investigators and Study Group
Published in:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.13299
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
the CVD-REAL Investigators and Study Group (2018). Rates of myocardial infarction and stroke in patients
initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice:
Results from the CVD-REAL study. Diabetes, Obesity and Metabolism, 20(8), 1983-1987. DOI:
10.1111/dom.13299
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 25. Aug. 2018
BR I E F R E POR T
Rates of myocardial infarction and stroke in patients
initiating treatment with SGLT2-inhibitors versus other
glucose-lowering agents in real-world clinical practice:
Results from the CVD-REAL study
Mikhail Kosiborod MD1 | Kåre I. Birkeland MD2 | Matthew A. Cavender MD3 |
Alex Z. Fu PhD4 | John P. Wilding MD5 | Kamlesh Khunti MD6 | Reinhard W. Holl MD7 |
Anna Norhammar MD8,9 | Marit E. Jørgensen MD10,11 | Eric T. Wittbrodt PharmD12 |
Marcus Thuresson PhD13 | Johan Bodegård MD14 | Niklas Hammar PhD8,15 |
Peter Fenici MD16 | on behalf of the CVD-REAL Investigators and Study Group*
1Department of Cardiovascular Diseases, Saint
Luke's Mid America Heart Institute and
University of Missouri-Kansas City, Kansas
City, Missouri
2University of Oslo and Oslo University
Hospital, Oslo, Norway
3Department of Medicine, University of North
Carolina, Chapel Hill, North Carolina
4Georgetown University Medical Center,
Washington, District of Columbia
5Obesity and Endocrinology Research Group,
University of Liverpool, Liverpool, UK
6Leicester Diabetes Centre, University of
Leicester, Leicester, UK
7Institute of Epidemiology and Medical
Biometry, University of Ulm, Ulm, Germany
8Karolinska Institutet, Stockholm, Sweden
9Capio S:t Görans Hospital, Stockholm,
Sweden
10Steno Diabetes Center, Copenhagen,
Denmark
11National Institute of Public Health, Southern
Denmark University, Odense, Denmark
12Health Economics and Outcomes Research,
AstraZeneca, Wilmington, Delaware
13Statisticon AB, Uppsala, Sweden
14AstraZeneca Nordic-Baltic, Oslo, Norway
15AstraZeneca R&D, Gothenburg, Sweden
16Global Medicines Development,
AstraZeneca, Cambridge, UK
The multinational, observational CVD-REAL study recently showed that initiation of sodium-
glucose co-transporter-2 inhibitors (SGLT-2i) was associated with significantly lower rates of
death and heart failure vs other glucose-lowering drugs (oGLDs). This sub-analysis of the CVD-
REAL study sought to determine the association between initiation of SGLT-2i vs oGLDs and
rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers
from the USA, Sweden, Norway and Denmark were used to identify patients with T2D who
newly initiated treatment with SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs.
A non-parsimonious propensity score was developed within each country to predict initiation
of SGLT-2i, and patients were matched 1:1 in the treatment groups. Pooled hazard ratios (HRs)
and 95% CIs were generated using Cox regression models. Overall, 205 160 patients were
included. In the intent-to-treat analysis, over 188 551 and 188 678 person-years of follow-up
(MI and stroke, respectively), there were 1077 MI and 968 stroke events. Initiation of SGLT-2i
vs oGLD was associated with a modestly lower risk of MI and stroke (MI: HR, 0.85; 95%CI,
0.72-1.00; P = .05; Stroke: HR, 0.83; 95% CI, 0.71-0.97; P = .02). These findings complement
the results of the cardiovascular outcomes trials, and offer additional reassurance with regard
to the cardiovascular effects of SGLT-2i, specifically as it relates to ischaemic events.
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1 | INTRODUCTION
Despite advances in prevention, cardiovascular disease remains the
leading cause of mortality and morbidity in patients with type 2 diabetes
(T2D). Two large randomized controlled trials (RCTs) of sodium-glucose
co-transporter-2 inhibitors (SGLT-2i; empagliflozin and canagliflozin)
have shown significant reductions in major adverse cardiac events, as
well as in hospitalizations for heart failure.1,2 The rates of non-fatal
myocardial infarction (MI) were numerically lower with both empagliflo-
zin and canagliflozin vs placebo; the point estimates for non-fatal stroke
numerically favoured placebo vs empagliflozin in the EMPA-REG OUT-
COME trial, and canagliflozin vs placebo in the CANVAS Program,
although none of these differences was statistically significant.1,2
Recently, the The Comparative Effectiveness of Cardiovascular
Outcomes (CVD-REAL) study, a multinational, observational study of
over 300 000 patients, found that initiation of SGLT-2i was associ-
ated with a significant reduction in death and heart failure when com-
pared to other glucose-lowering drugs (oGLDs).3 Observational data
from Nordic countries (CVD-REAL Nordic) has shown non-significant
point estimates in favour of SGLT-2i for MI and stroke, using some-
what different statistical methods, and with dapagliflozin dominating
the SGLT-2i group.4,5 However, the effects of SGLT-2i on athero-
thrombotic events in the larger CVD-REAL cohort, including patients
from the USA, with a broader representation of SGLT-2i compounds,
have not been explored previously. Accordingly, in this analysis of
global CVD-REAL data, we sought to determine the association
between initiation of SGLT-2i vs oGLDs and MI and stroke events.
2 | METHODS
The CVD-REAL study design has been described previously.3 For this
analysis, adult patients with T2D who newly initiated treatment with
SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs were
identified from medical records, claims and national registers collected
from 4 countries (USA, Sweden, Norway and Denmark). Because of
small numbers of patients and events in Germany and the United King-
dom, we elected not to include data from these countries in this analy-
sis. A non-parsimonious propensity score was developed separately
within each country to predict the likelihood of receiving a prescription
for an SGLT-2i, and patients were matched 1:1 in the 2 treatment
groups. In the main on-treatment analysis, patients were followed from
the index date (initiation of the SGLT-2i or oGLD) until completion of
treatment, occurrence of an outcome event, death or censoring. The
endpoints of interest were time to MI and stroke. Pooled hazard ratios
(HRs) and 95% confidence intervals (CIs) for each endpoint were
generated using Cox regression models, with inverse variance weighting
for each country. In a sensitivity analysis, an intent-to-treat (ITT)
approach was used, in which patients were followed after discontinua-
tion of index treatment. Analyses of de-identified data were conducted
in accordance with local laws and regulations, and received approvals
from the respective Scientific/Ethics/Data Protection Committees.
3 | RESULTS
After propensity-score matching, 205 160 patients were included in
the analysis (102 580 in each group), and baseline characteristics were
well balanced between the 2 groups. Among participants, the mean
age was 57 years, 43% were female, 14% had documented cardiovas-
cular disease before SGLT-2i or oGLD initiation. In the SGLT-2i group,
of the total exposure time, 49% of patients received dapagliflozin,
44% canagliflozin and 7% empagliflozin. There was significant geo-
graphical variation with regard to the specific SGLT-2i used, with
canagliflozin used predominately (75%) in the USA, and dapagliflozin
used predominately (90%) in Europe. In patients initiating treatment
with oGLDs, the most commonly used classes were insulin (34%),
dipeptidyl peptidase-4 (DPP-4) inhibitors (18%), sulfonylureas (17%),
glucagon-like peptide-1 receptor agonists (14%) and metformin (12%).
For the on-treatment analysis, the mean follow-up time was
254 days in the SGLT-2i group and 232 days in the oGLD group.
Over 136 524 and 136 626 person-years of follow-up (MI and
stroke, respectively), there were 779 MIs and 674 strokes (event rate
[ER], 0.57/ and 0.49/100 person-years, respectively). Initiation of
treatment with SGLT-2i vs oGLD was associated with a lower risk of
MI and stroke (MI: ER, 0.49/100 person-years for SGLT-2i vs
0.66/100 person-years for oGLD; HR, 0.78; 95% CI, 0.65-0.95;
P = .01 [Figure 1A]; Stroke: ER, 0.42/100 person-years for SGLT-2i
vs 0.58/100 person-years for oGLD; HR, 0.80; 95%CI, 0.66-0.97;
P = .02) [Figure 1B], with no evidence of heterogeneity by country.
In the ITT analysis, mean follow-up time was 339 days in the SGLT-
2i group and 332 days in the oGLD group. Over 188 551 and 188 678
person-years of follow-up (MI and stroke, respectively), there were 1077
MIs and 968 strokes (ER, 0.57/ and 0.51/100 person-years, respectively).
Initiation of treatment with SGLT-2i vs oGLD was associated with a lower
risk of MI and stroke (MI: ER, 0.52/100 person-years for SGLT-2i vs
0.62/100 person-years for oGLD; HR, 0.85; 95% CI, 0.72-1.00; P = .05; [-
Figure 1C]; Stroke: ER, 0.45/100 person-years for SGLT-2i vs 0.57/100
person-years for oGLD; HR, 0.83; 95% CI, 0.71-0.97; P = .02 [Figure 1D]),
with no evidence of heterogeneity by country.
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4 | DISCUSSION
In summary, in this multinational study involving over 200 000 patients,
seen within real-world clinical practice, with a very large number of
ischaemic events, initiation of treatment with SGLT-2i vs oGLDwas asso-
ciated with modestly lower rates of MI and stroke. Although our patient
population differed from the EMPA-REG OUTCOME trial and the CAN-
VAS Program, with a lower prevalence of cardiovascular disease, and
thus lower event rates, our results were directionally and numerically
consistent with both studies with respect to MI,1,2 with a difference in
width of the confidence intervals that is probably related to the greater
absolute number of events in our study. Our data were also directionally
and numerically consistent with the CANVAS Program with respect to
stroke.1 Our study offers important incremental information with regard
to the association between SGLT-2i use and atherothrombotic events,
including MI and stroke, in a broad population of patients with T2D from
routine clinical practice. Although prior observational data from Nordic
countries (CVD-REAL Nordic) examined these relationships, and showed
numerically lower, non-significant point estimates for MI and stroke
favouring SGLT-2i vs oGLDs, as well as vs DPP-4 inhibitors, those inves-
tigations evaluated smaller patient samples and numbers of events, used
somewhat different statistical approaches, and dapagliflozin dominated
the SGLT-2i group.4,5 Our study substantially expands these findings in
the much larger CVD-REAL cohort, with a greater number of events, with
patients from the USA, and with a broader representation of SGLT-2i
compounds. Collectively, our findings complement the results of the
completed cardiovascular outcomes trials of SGLT-2i, and prior observa-
tional analyses, and offer additional reassurance with regard to the car-
diovascular effects of SGLT-2i, specifically as it relates to ischaemic
events, especially stroke, for which concerns had been raised previously
based on a small numerical excess of stroke events with empagliflozin vs
placebo, which was not statistically significant.2
The results of our study should be considered in the context of sev-
eral potential limitations. First, given the observational nature of the ana-
lyses, and despite robust statistical techniques, including 1:1 propensity
matching, a possibility of residual, unmeasured confounding cannot be
FIGURE 1 Event rates, unadjusted hazard ratios and 95% CIs for acute myocardial infarction (A) and stroke (B) in the on-treatment population,
and for acute myocardial infarction (C) and stroke (D) in the ITT population. Abbreviations: ER, event rate; oGLD, other glucose-lowering drug;
P-Y, person-years; SGLT-2i, sodium-glucose transporter-2 inhibitors
KOSIBOROD ET AL. 1985
definitively excluded. Second, despite a large number of accrued patient-
years of follow up, the average duration of follow-up was relatively lim-
ited, as SGLT-2i use in real-world practice is still recent; longer-term
follow-up will be needed to evaluate whether effects are sustained over
time. Finally, given that CVD-REAL is a large, multinational pharmaco-
epidemiologic comparative effectiveness study, it was not designed to
examine the potential mechanisms linking the use of SGLT-2i and associ-
ated cardiovascular benefits. However, it is highly unlikely that glucose
lowering per se is behind the lower risk of cardiovascular events. As an
example, prior analyses from the EMPA-REG OUTCOME trial have dem-
onstrated little mediation effect of HbA1c on the cardiovascular benefits
of empagliflozin.6 Potential mechanisms may involve reductions in oxida-
tive stress, improvement in endothelial function, neuro-hormonal modu-
lation and anti-inflammatory effects, among others.7–11 A metabolic
hypothesis has also been proposed, suggesting that a shift in myocardial
metabolism from glucose and free fatty acids to ketones may contribute
to the cardiovascular benefits of SGLT-2i.12 Importantly, this knowledge
gap is being examined by mechanistic investigations across the SGLT-2i
class, with more information forthcoming in the near future.
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